Ginkgo Bioworks inks $290 mln Series E
Boston-based Ginkgo Bioworks, an organism company, has secured $290 million in Series E financing. The investors included T. Rowe Price Associates, Inc.
19 September 2019•1 min read
Boston-based Ginkgo Bioworks, an organism company, has secured $290 million in Series E financing. The investors included T. Rowe Price Associates, Inc.
Thoma Bravo, Vista back identity security assets; Hospital hacks spur add-on for Altaris-backed Tegria
6 November 2026 · 4 mins read
Velocity Capital Management backs founder Griffin Haddrill with stake in LV8, Mirage
6 November 2026 · 1 min read
Aterian’s Outlook Group completes acquisition of Graham-backed ABX’s Pewaukee packaging facility
6 November 2026 · 1 min read
FPE Capital’s NoBlue2 adds PeopleWalking’s Spanish NetSuite business in Europe push
6 November 2026 · 1 min read
PE targets identity security as AI transforms threats: 6 deals
6 November 2026 · 3 mins read
LDC backs London management consultancy Moorhouse after sale by Expleo
6 November 2026 · 2 mins read
PAI and ICG receive VKR Holding offer for window shutter maker StellaGroup
6 November 2026 · 2 mins read
